Advertisement
Screener

TRANSCODE THERAPEUTICS, INC. (RNAZ) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

TRANSCODE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

TRANSCODE THERAPEUTICS, INC. (RNAZ) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 67 shares for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-14.

Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-14

  • TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares.
  • TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 4.00 shares, a 99.98% decline year-over-year.
  • TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was -401.00 shares, a 249.07% decline year-over-year.
  • TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 464.00 shares, a 12.08% increase year-over-year.
  • TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 83.00 shares, a 591.67% increase from fiscal 2023.
  • TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 12.00 shares.
  • TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 78.98K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 1 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed
2025-12-310.00 shares
derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-14
4.00 shares
derived: sum of 2 quarters · filed 2026-08-14
-397.00 shares
derived: sum of 3 quarters · filed 2026-08-14
67.00 shares
10-Q · filed 2026-08-14
2025-09-304.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
-397.00 shares
derived: sum of 2 quarters · filed 2025-11-14
67.00 shares
10-Q · filed 2025-11-14
-19.01K shares
derived: sum of 4 quarters · filed 2026-04-15
2025-06-30-401.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
63.00 shares
10-Q · filed 2025-08-14
-19.02K shares
derived: sum of 3 quarters · filed 2026-04-15
-537.00 shares
derived: sum of 4 quarters · filed 2026-04-15
2025-03-31464.00 shares
10-Q · filed 2025-05-14
-18.62K shares
derived: sum of 2 quarters · filed 2026-04-15
-136.00 shares
derived: sum of 3 quarters · filed 2026-04-15
133.00 shares
derived: sum of 4 quarters · filed 2026-04-15
2024-12-31-19.08K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
-600.00 shares
derived: sum of 2 quarters · filed 2026-04-15
-331.00 shares
derived: sum of 3 quarters · filed 2026-04-15
83.00 shares
10-K · filed 2026-04-15
1.56K shares
10-K · filed 2025-04-15
2024-09-3018.48K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
18.75K shares
derived: sum of 2 quarters · filed 2024-11-14
19.16K shares
10-Q · filed 2024-11-14
13.90K shares
derived: sum of 4 quarters · filed 2025-04-15
2024-06-30269.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
683.00 shares
10-Q · filed 2024-08-14
-4.58K shares
derived: sum of 3 quarters · filed 2025-04-15
2024-03-31414.00 shares
10-Q · filed 2024-05-15
-4.85K shares
derived: sum of 2 quarters · filed 2025-04-15
2023-12-31-5.26K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15
12.00 shares
10-K · filed 2025-04-15
393.00 shares
10-K · filed 2024-04-01
2023-09-305.28K shares
10-Q · filed 2023-11-14
2021-12-3178.98K shares
10-Q · filed 2022-05-16
78.98K shares
10-K · filed 2023-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
NANOVIRICIDES, INC. (NNVC)United States$0.031B
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
NextCure, Inc. (NXTC)United States$0.024B-0.15
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87